Researchers at WashU Medicine have reduced scar formation and improved heart function in mouse models of heart failure using a monoclonal antibody treatment. Untreated mice develop major scarring ...

A new study from Washington University School of Medicine in St. Louis suggests that a type of immunotherapy — similar to that approved by the Food ...

A new study from Washington University School of Medicine in St. Louis suggests that a type of immunotherapy—similar to that ...

Abrysvo® and Arexvy® are Health Canada-approved vaccines for preventing RSV-related lower respiratory tract disease in individuals 60 years of age and older, currently available for high-risk older ...

The merger will create a specialty company, REGiMMUNE/Kiji TX, for regulatory T cells.

Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a 'magic bullet' strategy ...

Q3 2024 Earnings Call Transcript October 22, 2024 Danaher Corporation beats earnings expectations. Reported EPS is $1.71, ...

Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases, today announced a poster presentation on HMBD-802, a novel ...

Interview with Nicolas Poirier, CEO at OSE Immunotherapeutics a biotech with a compound that is a therapeutic cancer vaccine, ...

Clesrovimab, formerly known as MK-1654, is an extended half-life RSV fusion glycoprotein neutralizing monoclonal antibody.

Regeneron spent $5 billion repurchasing shares from Sanofi in May 2020 and $900 million repurchasing global rights to Libtayo in July 2022, yet a windfall from sales of its Covid antibody cocktail as ...